PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL THERAPY DURING PREGNANCY (PACTG)

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 这是一项前瞻性研究，旨在描述目前用于妊娠HIV感染女性临床护理的选定抗逆转录病毒药物在妊娠期间的药代动力学参数，并确定这些抗逆转录病毒药物的治疗性给药方案是否在妊娠期间产生足够的药物暴露，与a）非妊娠成人的历史数据;和B）研究队列中相同女性在产后期间相比。 次要目的是比较分娩时脐带血和母体血浆中的抗逆转录病毒药物浓度，并通过测定6 B-羟基皮质醇与皮质醇的比值间接评估细胞色素P450 3A 4的诱导。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a prospective study to describe the pharmacokinetic parameters during pregnancy of selected antiretroviral drugs currently used in the clinical care of pregnant HIV infected women, and to determine if therapeutic dosing regimes of these antiretroviral drugs produce adequate drug exposure during pregnancy compared to a) historical data from non-pregnant adults; and b) the same women in the study cohorts during the post-partum period. The secondary objectives are to compare antiretroviral drug concentrations in plasma from cord blood in those in maternal plasma at the time of delivery and to indirectly assess the induction of cytochrome P450 3A4 by determinie the ratio in ruine of 6B-hydroxycortisol to cortisol.